Table 1 Baseline characteristics before and after matching
From: Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Variable | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
Fingolimod | Dimethyl fumarate | SMD | Fingolimod | Dimethyl fumarate | SMD | |
n | 1075 | 1038 | 961 (89%a) | 961 (93%a) | ||
Age, mean, years (SD) | 39.5 (11.5) | 40.6 (11.6 | 0.09 | 40.2 (11.3) | 40.4 (11.5) | 0.02 |
Gender (female, %) | 733 (68%) | 753 (72%) | 0.10 | 672 (70%) | 689 (72%) | 0.01 |
Disease duration, mean, years (SD) | 7.9 (8.4) | 8.4 (8.0) | 0.07 | 8.1 (8.4) | 8.3 (8.0) | 0.02 |
EDSS, median (IQR) | 2.0 (1.5–3.0) | 2.0 (1.5–3.0) | 0.03 | 2.0 (1.5–3.0) | 2.0 (1.5–3.0) | 0.01 |
Preceding treatment, n (%) | ||||||
Naïve | 501 (47%) | 393 (38%) | 414 (43%) | 386 (40%) | ||
IFN beta 1a i.m. | 102 (10%) | 133 (13%) | 100 (10%) | 116 (12%) | ||
IFN beta 1a s.c. | 128 (12%) | 151 (15%) | 127 (13%) | 131 (14%) | ||
PEG-IFN beta 1a s.c. | 11 (1%) | 6 (< 1%) | 8 (< 1%) | 6 (< 1%) | ||
IFN beta 1b s.c. | 84 (8%) | 98 (9%) | 80 (8%) | 88 (9%) | ||
Glatiramer acetate | 90 (8%) | 102 (10%) | 85 (9%) | 88 (9%) | ||
Teriflunomide | 25 (2%) | 35 (3%) | 24 (3%) | 32 (3%) | ||
Daclizumab | 4 (< 1%) | 2 (< 1%) | 2 (< 1%) | 2 (< 1%) | ||
Ocrelizumab | 1 (< 1%) | 0 | 0 | 0 | ||
Natalizumab | 129 (12%) | 151 (15%) | 121 (13%) | 112 (12%) | ||
Number of relapses in the year before baseline, mean (SD) | 0.6 (0.9) | 0.5 (0.8) | 0.10 | 0.6 (0.8) | 0.6 (0.8) | 0.01 |
Follow up, median, years (IQR) | 1.8 (0.9–2.8) | 1.8 (0.8–2.8) | 0.9 (0.8–1.8)b | 0.9 (0.8–1.8)b | ||